NRx Pharmaceuticals Inc

NRx Pharmaceuticals, Inc. is a biotechnology company headquartered in Wilmington, Delaware. The company is privately held and employs 21 people. NRx Pharmaceuticals focuses on developing novel therapeutics for patients with significant unmet medical needs. Their primary product candidate, NRX-101, is an investigational medicine being studied for the treatment of severely depressed patients experiencing acute suicidal ideation and behavior (ASIB), particularly those who have not fully responded to initial ketamine or other approved treatments. The U.S. Food and Drug Administration (FDA) has recognized the potential of NRX-101 by granting Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support. This signifies the drug's potential to offer significant advancements in treating severely depressed patients at high risk of suicide. For more information about NRx Pharmaceuticals and their ongoing clinical trials, please visit their website at nrxpharma.com.